Pfizer Completes Acquisition of Excaliard
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring.
Bristol-Myers Squibb Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals, one of the Janssen Pharmaceutical Companies, to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435,
Novartis Foundation symposium looks at impact of Information and Communication Technology
- Details
- Category: Novartis
Today a panel of experts in media, technology and healthcare are gathering to discuss the topic "New media - drivers of democratization and development?" at the 2011 Novartis Foundation for Sustainable Development (NFSD) symposium in Basel, Switzerland.
Understand Barriers to Progression of Insulin Treatment
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) is conducting the first major international, prospective observational study designed to understand the real-world obstacles that people with type 2 diabetes face that prevent them from reaching their ultimate treatment goals.
Ranbaxy announces launch of Atorvastatin, generic Lipitor®, in the U.S.
- Details
- Category: Product
Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) ("Ranbaxy"), today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin and has launched the product in the U.S. market.
Sanofi Confirms its Decades-Long Commitment to the Fight against Malaria
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) confirmed its decades-long commitment to the fight against malaria at the opening of 10th Edition of the Pan-African Conference against Malaria.
AstraZeneca commits an additional $100 million to venture capital arm MedImmune Ventures
- Details
- Category: AstraZeneca
AstraZeneca has committed an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million.
More Pharma News ...
- Pradaxa® awarded Prix Galien for most innovative product in Canada
- Lilly Provides Additional Funding to Infectious Disease Research Institute to Identify New Tuberculosis Therapies
- Merck Sends Assistance to Flood-Ravaged Thailand
- Pfizer to Acquire Excaliard Pharmaceuticals
- Enbrel® (etanercept) Patent Issued
- FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer
- Pfizer Wins Corporate Citizenship Award For Global Health Partnerships Program